Aqemia Advances Epitranscriptomics Programs and Expands into Small-Molecule RNA Targeting with $7.4 Million Grant
Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Building on successes in epitranscriptomics, Aqemia aims to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets. In parallel with advancing RNA-focused initiatives, the company continues to drive innovation in its broader pipeline, including protein-targeting programs.
AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK
AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom).
AQEMIA Boosts Series A Funding to €60M to Accelerate on its Proprietary Therapeutic Pipeline
AQEMIA continues to grow rapidly in its effort to discover new drugs with their generative-AI fueled by deep physics. After raising €30M last year, the tech-enabled drug discovery company today announced it has received an additional €30 million investment, which brings the Series A funding round to €60 million. This investment in AQEMIA is being led by Wendel Growth and also includes commitments by the company’s long-standing partners: Bpifrance Large Venture, Eurazeo and Elaia.
AQEMIA Announces a Major Multi-year Collaboration of $140 Million With Sanofi
AQEMIA, a pioneering pharmatech company leveraging AI and quantum-inspired physics to accelerate the discovery of small molecule drug candidates with higher probability of success in the clinic, announces a multi-year research collaboration with the global pharmaceutical company Sanofi. The collaboration aims at discovering small molecule drug candidates across several therapeutic areas. AQEMIA will leverage its unique platform that combines deep physics with generative AI at scale to identify the right chemical molecules for therapeutic targets of interest to Sanofi.
Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology
Servier and Aqemia announce the extension of their new-molecule discovery collaboration on an undruggable therapeutic target in immuno-oncology.
Aqemia Raises €30M to Scale its Deep Physics and AI Enabled Drug Discovery Pipeline
Aqemia raises €30 million in a Series A funding round led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of Elaia its historic investor. This financing will further support Aqemia’s core mission: to massively scale drug discovery, through a first-in-class technological platform combining quantum-inspired physics and machine learning.
Aqemia Announces an Extension of Its First Collaboration With Sanofi About AI and Quantum Physics-driven Drug Discovery in Oncology
Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with Sanofi.
Aqemia Announces Pilot Study with Janssen to Utilize Aqemia’s Physics-driven Drug Discovery Technology
Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen.
